Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J1302 |
Short Description | Inj, sutimlimab-jome, 10 mg |
Long Description | Injection, sutimlimab-jome, 10 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2022-10-01 |
Date Added | 2022-10-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
80203034701 | J1302 | Inj, sutimlimab-jome, 10 mg | Enjaymo | BIOVERATIV USA INC | 10 MG | 22 | 1 | 110 | 110 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 10 MG |
HCPCS/CPT Billing Units | 0.1 |
Total doses ordered | |
Billing Units | 0.1 |
Drug Details
-
Sutimlimab-jome injection is used to treat the breakdown of red blood cells in adults with cold agglutinin disease (CAD; an inherited condition in which the immune system mistakenly attacks and destroys its own red blood cells). Sutimlimab-jome is in a class of medications called complement inhibitors. It works by blocking the activity of the part of the immune system that may damage red blood cells.